The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis: a Validation Study

Status: Recruiting
Location: See all (19) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Aged over 18 Years

• Diagnosed with gMG at screening with generalized muscle weakness meeting the clinical criteria for diagnosis of MG, as defined by the MGFA Clinical Classification Class II, III, or IV, and likely not in need of a respirator for the duration of the study, as judged by the investigator

• With positive serologic testing for anti-AChR autoantibody at screening

• Have read the information sheet and signed the informed consent form

• Own a personal smartphone which software version is above 13 for IOS and 8 for Android included

• Able to use a smartphone

• Able to read language in which the mobile application is available (French, English, Spanish) and able to understand pictograms

Locations
United States
Colorado
University of Colorado Denver
RECRUITING
Aurora
Florida
University of Florida Health
RECRUITING
Jacksonville
Indiana
HealthParterns Institute
COMPLETED
Bloomington
Indiana University Health
RECRUITING
Indianapolis
Kentucky
University of Kentucky
RECRUITING
Lexington
North Carolina
Duke University
RECRUITING
Durham
New York
Neurological Associates of Long Island, P.C.
RECRUITING
Lake Success
Oregon
OHSU
RECRUITING
Portland
Pennsylvania
Thomas Jefferson University
RECRUITING
Philadelphia
Tennessee
The University of Tennessee Medical Center
NOT_YET_RECRUITING
Knoxville
Vanderbilt Health
RECRUITING
Nashville
Other Locations
France
Hôpital Raymond Poincaré
RECRUITING
Garches
CHU Grenoble
NOT_YET_RECRUITING
Grenoble
Hôpital Salengro
RECRUITING
Lille
CHRU Nancy
RECRUITING
Nancy
CHU Nantes
RECRUITING
Nantes
Pitié-Salpêtrière
RECRUITING
Paris
CHU de Strasbourg - Hôpital de Hautepierre
COMPLETED
Strasbourg
CHU Toulouse
RECRUITING
Toulouse
Contact Information
Primary
Pr Laforet
pascal.laforet@aphp.fr
+33147107752
Time Frame
Start Date: 2024-01-24
Estimated Completion Date: 2026-09-24
Participants
Target number of participants: 144
Treatments
Experimental: MG patients
MG patients will perform 3 in-clinic visits and use the ME\&MG app at-home during 12 months
Other: Healthy volunteers
Healthy volunteers will perform one in-clinic visit and will use the app at-home once
Related Therapeutic Areas
Sponsors
Leads: Ad scientiam

This content was sourced from clinicaltrials.gov